A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with immune checkpoint inhibition (The LuSato1 Study).

Start Date30 Jun 2023

Sponsor / Collaborator-

100 Clinical Results associated with SSO-120

100 Translational Medicine associated with SSO-120

100 Patents (Medical) associated with SSO-120

Literatures (Medical) associated with SSO-120

01 Jan 2024·Theranostics

Theranostics with somatostatin receptor antagonists in SCLC: Correlation of ⁶⁸Ga-SSO120 PET with immunohistochemistry and survival

Article

Author: Mavroeidi, Ilektra Antonia ; Nader, Michael ; Kersting, David ; Wienker, Johannes ; Bölükbas, Servet ; Theegarten, Dirk ; Hautzel, Hubertus ; Romanowicz, Anna ; Oezkan, Filiz ; Stuschke, Martin ; Haake, Tristan ; Umutlu, Lale ; Opitz, Marcel ; Herrmann, Ken ; Fendler, Wolfgang P. ; Schuler, Martin ; Fendler, Wolfgang P ; Winantea, Jane ; Hamacher, Rainer ; Eberhardt, Wilfried E E ; Metzenmacher, Martin ; Eberhardt, Wilfried E. E. ; Siveke, Jens ; Darwiche, Kaid ; Wiesweg, Marcel

Rationale: Positron Emission Tomography (PET) using the somatostatin receptor 2 (SSTR2)-antagonist satoreotide trizoxetan (⁶⁸Ga-SSO120) is a novel, promising imaging modality for small-cell lung cancer (SCLC), which holds potential for theranostic applications. This study aims to correlate uptake in PET imaging with SSTR2 expression in immunohistochemistry (IHC) and to assess the prognostic value of ⁶⁸Ga-SSO120 PET at initial staging of patients with SCLC. Methods: We analyzed patients who underwent ⁶⁸Ga-SSO120 PET/CT during initial diagnostic workup of SCLC as part of institutional standard-of-care. SSTR2 expression in IHC was evaluated on a 4-level scale and correlated with normalized standardized uptake values and tumor-to-liver ratios (SUV_max and TLR_peak) in ⁶⁸Ga-SSO120 PET on a lesion level. Highest lesion SUV_max/TLR_peak per patient, SSTR2 score in IHC, M status according to TNM classification, and other parameters were analyzed for association with overall survival (OS) and time to treatment failure (TTF) by univariate, multivariate (cut-off values were identified on data for best separation), and stratified Cox regression. Results: We included 54 patients (24 men/30 women, median age 65 years, 21 M0/33 M1 according to TNM classification). In 43 patients with available surplus tumor tissue samples, hottest lesion SUV_max/TLR_peak showed a significant correlation with the level of SSTR2-expression by tumor cells in IHC (Spearman's rho 0.86/0.81, both p < 0.001; ANOVA p < 0.001). High SSTR2 expression in IHC, ⁶⁸Ga-SSO120 SUV_max and TLR_peak of the hottest lesion per patient, whole-body TLR_mean, MTV, TLG, M status, and serum LDH showed a significant association with inferior TTF/OS in univariate analysis. In separate multivariate Cox regression (including sex, age, M stage, and LDH) higher hottest-lesion TLR_peak showed a significant association with shorter OS (HR = 0.26, 95%CI: 0.08-0.84, p = 0.02) and SSTR2 expression in IHC with significantly shorter TTF (HR = 0.24, 95%CI: 0.08-0.71, p = 0.001) and OS (HR = 0.22, 95%CI: 0.06-0.84, p = 0.03). In total, 12 patients (22.2%) showed low (< 1), 21 (38.9%) intermediate (≥ 1 but < 2), 14 (25.9%) high (≥ 2 but < 5), and 7 (13.0%) very high (≥ 5) whole-body mean TLR_mean. Conclusion: In patients with SCLC, SSTR2 expression assessed by ⁶⁸Ga-SSO120 PET and by IHC were closely correlated and associated with shorter survival. More than 75% of patients showed higher whole-body ⁶⁸Ga-SSO120 tumor uptake than liver uptake and almost 40% high or very high uptake, possibly paving the way towards theranostic applications.

01 Dec 2017·Ecology and EvolutionQ2 · BIOLOGY

Establishing the phylogeny of Prochlorococcus with a new alignment‐free method

Q2 · BIOLOGY

ArticleOA

Author: Yau, Stephen S.‐T. ; He, Rong L. ; Tian, Kun ; Zhao, Xin

AbstractProchlorococcus marinus, one of the most abundant marine cyanobacteria in the global ocean, is classified into low‐light (LL) and high‐light (HL) adapted ecotypes. These two adapted ecotypes differ in their ecophysiological characteristics, especially whether adapted for growth at high‐light or low‐light intensities. However, some evolutionary relationships of Prochlorococcus phylogeny remain to be resolved, such as whether the strains SS120 and MIT9211 form a monophyletic group. We use the Natural Vector (NV) method to represent the sequence in order to identify the phylogeny of the Prochlorococcus. The natural vector method is alignment free without any model assumptions. This study added the covariances of amino acids in protein sequence to the natural vector method. Based on these new natural vectors, we can compute the Hausdorff distance between the two clades which represents the dissimilarity. This method enables us to systematically analyze both the dataset of ribosomal proteomes and the dataset of 16s‐23s rRNA sequences in order to reconstruct the phylogeny of Prochlorococcus. Furthermore, we apply classification to inspect the relationship of SS120 and MIT9211. From the reconstructed phylogenetic trees and classification results, we may conclude that the SS120 does not cluster with MIT9211. This study demonstrates a new method for performing phylogenetic analysis. The results confirm that these two strains do not form a monophyletic clade in the phylogeny of Prochlorococcus.

19 Aug 2003·Proceedings of the National Academy of SciencesQ1 · CROSS-FIELD

Genome sequence of the cyanobacterium Prochlorococcus marinus SS120, a nearly minimal oxyphototrophic genome

Q1 · CROSS-FIELD

Article

Author: Dufresne, Alexis ; Le Gall, Florence ; Galperin, Michael Y. ; Makarova, Kira S. ; Artiguenave, François ; Axmann, Ilka M. ; Partensky, Frédéric ; Koonin, Eugene V. ; de Marsac, Nicole Tandeau ; Robert, Catherine ; Salanoubat, Marcel ; Wincker, Patrick ; Rogozin, Igor B. ; Weissenbach, Jean ; Oztas, Sophie ; Ostrowski, Martin ; Duprat, Simone ; Barbe, Valérie ; Hess, Wolfgang R. ; Scanlan, David J. ; Wolf, Yuri I.

Prochlorococcus marinus , the dominant photosynthetic organism in the ocean, is found in two main ecological forms: high-light-adapted genotypes in the upper part of the water column and low-light-adapted genotypes at the bottom of the illuminated layer. P. marinus SS120, the complete genome sequence reported here, is an extremely low-light-adapted form. The genome of P. marinus SS120 is composed of a single circular chromosome of 1,751,080 bp with an average G+C content of 36.4%. It contains 1,884 predicted protein-coding genes with an average size of 825 bp, a single rRNA operon, and 40 tRNA genes. Together with the 1.66-Mbp genome of P. marinus MED4, the genome of P. marinus SS120 is one of the two smallest genomes of a photosynthetic organism known to date. It lacks many genes that are involved in photosynthesis, DNA repair, solute uptake, intermediary metabolism, motility, phototaxis, and other functions that are conserved among other cyanobacteria. Systems of signal transduction and environmental stress response show a particularly drastic reduction in the number of components, even taking into account the small size of the SS120 genome. In contrast, housekeeping genes, which encode enzymes of amino acid, nucleotide, cofactor, and cell wall biosynthesis, are all present. Because of its remarkable compactness, the genome of P. marinus SS120 might approximate the minimal gene complement of a photosynthetic organism.

100 Deals associated with SSO-120

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuroblastoma	Phase 1	DE	Ariceum Therapeutics GmbHStartup	21 Jul 2022
Solid tumor	Phase 1	DE	Ariceum Therapeutics GmbHStartup	21 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2023	Not Applicable	Small Cell Lung Cancer	-	68Ga-SSO-12068Ga-Satoreotide (68Ga-SSO-120 PET/CT)	nsfgtselhj(hnxlpzhrlp) = mrbzqtwdig xutpjfecff (jilhzdbvrc ) View more	-	28 Aug 2023
				FDG68Ga-Satoreotide (FDG PET/CT)	yyqqwretoo(wrgpitmzmz) = rkopdvonra plmnxbmgal (rnqcyqsryw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SSO-120

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation